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Mediation of proliferating cell nuclear antigen
(PCNA)-dependent DNA replication through a conserved
p21(Cip1)-like PCNA-binding motif present in the third subunit
of human DNA polymerase delta
Abstract
The subunit that mediates binding of proliferating cell nuclear antigen (PCNA) to human DNA
polymerase delta has not been clearly defined. We show that the third subunit of human DNA
polymerase delta, p66, interacts with PCNA through a canonical PCNA-binding sequence located in its
C terminus. Conversely, p66 interacts with the domain-interconnecting loop of PCNA, a region
previously shown to be important for DNA polymerase delta activity and for binding of the cell cycle
inhibitor p21(Cip1). In accordance with this, a peptide containing the PCNA-binding domain of
p21(Cip1) inhibited p66 binding to PCNA and the activity of native three-subunit DNA polymerase
delta. Furthermore, pull-down assays showed that DNA polymerase delta requires p66 for interaction
with PCNA. More importantly, only reconstituted three-subunit DNA polymerase delta displayed
PCNA-dependent DNA replication that could be inhibited by the PCNA-binding domain of p21(Cip1).
Direct participation of p66 in PCNA-dependent DNA replication in vivo is demonstrated by
co-localization of p66 with PCNA and DNA polymerase delta within DNA replication foci. Finally, in
vitro phosphorylation of p66 by cyclin-dependent kinases suggests that p66 activity may be subject to
cell cycle-dependent regulation. These results suggest that p66 is the chief mediator of PCNA-dependent
DNA synthesis by DNA polymerase delta.
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The subunit that mediates binding of proliferating
cell nuclear antigen (PCNA) to human DNA polymerase
 has not been clearly defined. We show that the third
subunit of human DNA polymerase , p66, interacts with
PCNA through a canonical PCNA-binding sequence lo-
cated in its C terminus. Conversely, p66 interacts with
the domain-interconnecting loop of PCNA, a region pre-
viously shown to be important for DNA polymerase 
activity and for binding of the cell cycle inhibitor
p21Cip1. In accordance with this, a peptide containing
the PCNA-binding domain of p21Cip1 inhibited p66 bind-
ing to PCNA and the activity of native three-subunit
DNA polymerase . Furthermore, pull-down assays
showed that DNA polymerase  requires p66 for interac-
tion with PCNA. More importantly, only reconstituted
three-subunit DNA polymerase  displayed PCNA-de-
pendent DNA replication that could be inhibited by the
PCNA-binding domain of p21Cip1. Direct participation of
p66 in PCNA-dependent DNA replication in vivo is dem-
onstrated by co-localization of p66 with PCNA and DNA
polymerase  within DNA replication foci. Finally, in
vitro phosphorylation of p66 by cyclin-dependent ki-
nases suggests that p66 activity may be subject to cell
cycle-dependent regulation. These results suggest that
p66 is the chief mediator of PCNA-dependent DNA syn-
thesis by DNA polymerase .
DNA replication requires the recruitment of multiple com-
ponents during the S phase of the cell cycle. Of chief impor-
tance are DNA polymerases, of which three, , , and , have
been shown by genetic studies in the yeast Saccharomyces
cerevisiae to be essential for the replication of the eucaryotic
genome (1, 2). Among these, DNA polymerase -primase is the
only enzyme that can start DNA synthesis de novo. It is thus
ideally suited for the synthesis of short primers that serve to
initiate leading strand synthesis at the replication origin and
Okazaki fragments on the lagging strand (3, 4). Both DNA
polymerases  and  can elongate primers synthesized by DNA
polymerase  and appear to have overlapping or complemen-
tary functions (5). Although DNA polymerase  alone can rep-
licate both leading and lagging strands in vitro (5), mounting
evidence suggests that DNA polymerase  may be implicated in
DNA replication in ways that may not necessarily involve its
DNA polymerase activity (6–10).
We have been interested in how DNA polymerase  interacts
with other factors to accomplish replication of the mammalian
genome. Extensive research over a number of years has shown
that DNA polymerase  requires interactions with at least two
factors, a toroidal-shaped homotrimeric protein known as pro-
liferating cell nuclear antigen (PCNA)1 and a heteropentameric
complex termed replication factor C. In the presence of ATP,
replication factor C interacts with the 3 primer-template ter-
minus and recruits PCNA onto the DNA, creating a mobile
platform that tethers DNA polymerase  to the primer termi-
nus. Once bound to PCNA, DNA polymerase  acquires new
dynamic properties, including high processivity, low nonpro-
ductive binding to single-stranded DNA, and propinquity to
factors engaged in ancillary activities at the replication fork (5).
Replication complex formation involving PCNA, DNA polym-
erase , and replication factor C is inhibited by p21Cip1 (11, 12),
a Cdk inhibitor whose increased synthesis following DNA dam-
age results in mitotic arrest in the G1 phase of the cell cycle (13,
14). In contrast, the effect of p21Cip1 on nucleotide excision
repair, which requires PCNA-dependent DNA synthesis by
DNA polymerase , remains controversial (15, 16). The C-
terminal region of p21Cip1 contains the canonical PCNA-bind-
ing domain (17). A peptide containing this domain inhibits
DNA synthesis by DNA polymerase  in vitro (17–19). Crystal-
lographic studies have shown that the peptide interacts with
the domain-interconnecting loop of PCNA, a region that has
also been shown to mediate DNA polymerase  binding to
PCNA (20). These data strongly suggest that p21Cip1 inhibition
of DNA polymerase  involves competition between their re-
spective PCNA-binding domains for binding to PCNA. How-
ever, despite the fundamental importance of this interaction,
the identity of the subunit of mammalian DNA polymerase 
that mediates PCNA binding remains controversial.
All three DNA polymerases mentioned have complicated
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subunit compositions consisting of a large catalytic subunit and
smaller subunits whose functions in many cases remain to be
elucidated. DNA polymerase  from the yeast Schizosaccharo-
myces pombe consists of at least four subunits: Pol3, Cdc1,
Cdc27, and Cdm1 (21). The Cdc27 subunit was recognized early
on to contain a C-terminal sequence motif that shares signifi-
cant homology with the consensus PCNA-binding motif found
in a variety of PCNA-binding proteins such as p21Cip1, Fen1, 5
cytosine methyltransferase, and DNA ligase I (22). Since then,
the region has been shown to interact directly with PCNA and
to be essential for cell viability, indicating that Cdc27 plays an
essential function by bridging the catalytic subunit of DNA
polymerase  to PCNA (23). Likewise, purified DNA polymer-
ase  complexes from S. cerevisiae contain three subunits (24),
one of which, Pol32, has been shown to be the functional ho-
mologue of Cdc27 (25). In mammals, however, DNA polymerase
 has up until recently been consistently purified as a het-
erodimeric complex of only two subunits (26), a catalytic sub-
unit of 125 kDa and a small subunit of 48–50 kDa that display
homology respectively to Pol3 and Cdc1 of S. pombe. PCNA
stimulation of the two-subunit complex and the absence of a
visible Cdc27 homologue led to the identification of binding
sites for PCNA on the large subunit of human DNA polymerase
 (27). However, none of these binding sites display significant
homology to the canonical PCNA-binding site found in other
PCNA-binding proteins such as p21Cip1, although one of the
sites resembles the novel PCNA-binding site recently identified
by screening a random peptide library for PCNA-binding pro-
teins (28). The necessity of the small 48–50-kDa subunit for the
reconstitution of active two-subunit DNA polymerase  led to
the alternative suggestion that the PCNA-binding site was
located on the small subunit or was formed at the interface
between both subunits (29).
Recently, new purification procedures for DNA polymerase 
from mouse (30), calf thymus (31), and human cells (32) yielded
a novel subunit of 66–68 kDa, termed p66 or subunit C accord-
ing to the newly proposed nomenclature for DNA polymerase 
subunits (34). Here, we present results that strongly suggest
that this subunit mediates PCNA binding to DNA polymerase
 and corresponds to the subunit whose interaction with PCNA
is targeted by p21Cip1.
MATERIALS AND METHODS
Reagents, Peptides, Buffers, and Enzymes—Isopropyl--D-thiogalac-
topyranoside and dithiothreitol (DTT) were from ICN Biomedicals Inc.
Antibiotics were from Eurobio. ELISA plates (Maxisorb) were from
Nalgen-Nunc International. Restriction enzymes and bovine serum al-
bumin (BSA) (Fraction V) were from Roche Molecular Biochemicals.
Phosphate-buffered saline (PBS) tablets (pH 7.2) were from Life Tech-
nologies, Inc. Where indicated, protease inhibitors (ICN Biomedicals
Inc.) were added at the following concentrations: 5 g/ml antipain, 5
g/ml leupeptin, 5 g/ml aprotinin, and 5 g/ml pepstatin. Streptavidin
was from Promega. Streptavidin-agarose beads were from Sigma-Al-
drich. Nitrocellulose membranes (BioTrace NT 0.45 ) were from
Gelman Sciences. Ni-NTA agarose was from Qiagen. The synthetic
peptides had the following sequences: N-terminal biotinated p66
peptide, Btn-KGTAALGKANRQVSITGFFQRK; p21Cip1 peptide,
GRKRRQTSMTDFYHSKRRLIFS; and mutated p21Cip1 peptide,
GRKRRQTSATDFYHSKRRLIFSKRKP. The methionine to alanine
substitution in the mutated peptide is indicated in bold type. All pep-
tides were greater than 95% pure and were obtained from Sigma-
Genosys. Cyclin-Cdk complexes were a kind gift of Dr. Heinz-Peter
Nasheuer. Buffer PBS-T contained PBS plus 0.1% Tween 20, and buffer
PBS-TM was buffer PBS-T plus 5% skimmed milk. Mouse DNA
polymerase  complex was purified as described previously (30).
Antibodies—Monoclonal anti-p66 antibody was prepared by Q-BIO-
gene using recombinant p66 protein expressed in Escherichia coli. One
hybridoma clone (2C11) was selected for its ability to recognize p66 on
Western blots and immunoprecipitate p66 from mouse cell extracts.
Rabbit anti-serum directed against recombinant p50 (I4 527) was kindly
provided by Dr. Antero So.
Unless indicted otherwise, the antibodies were diluted as follows for
Western blot analyses: goat anti-p125 antibody (C-20, Santa Cruz Bio-
technology) at 1:1000; rabbit anti-p50 antibody at 1:1,000; rabbit anti-
phosphoserine antibodies (Zymed Laboratories Inc.) at 1:1000; and
mouse anti-phosphothreonine antibodies (Zymed Laboratories Inc.) at
1:1000.
Purification of His-tagged PCNA Protein—His-tagged PCNA protein
was purified as described previously (35) except that proteins eluted
from the Ni-NTA column were dialyzed at 4 °C against buffer contain-
ing 20 mM HEPES-KOH, pH 7.5, 1 mM DTT, 100 mM NaCl, and 10%
glycerol and charged onto a 1-ml Hi-Trap ion exchange column (Amer-
sham Pharmacia Biotech). PCNA was eluted at about 0.4 M NaCl after
applying a gradient of 0.1 M NaCl to 1 M NaCl in the same buffer to the
column at 4 °C. Biotination of PCNA and recombinant human RP-A
(replication protein A) was achieved by using the biotin labeling kit of
Roche Molecular Biochemicals according to the manufacturer’s
instructions.
Induction and Purification of Recombinant p66—The coding se-
quence of human-p66 was cloned into pET19b as described previously
(30), and the recombinant plasmid was transferred into E. coli BLR
DE3. Transformed cells were incubated at 37 °C with continual shaking
in 1 liter of LB medium containing 100 g/ml ampicillin and 40 mM
glucose. When the cells reached an A600 of about 0.3, the cells were
resuspended in 1 liter of LB medium containing 100 g/ml of ampicillin
and 1 mM isopropyl--D-thiogalactopyranoside. The culture was incu-
bated for 6 h at 37 °C. After centrifugation, the pellet was resuspended
in 50 ml of 50 mM Na2HPO4, 100 mM KCl, 0.1% Tween 20, 10 mM
-mercaptoethanol, 10 mM EDTA, 10 mM EGTA, 1 mM phenylmethyl-
sulfonyl fluoride, 200 g/ml lysozyme, and protease inhibitors. After 20
min on ice, the suspension was sonicated and centrifuged at 19,000  g
for 10 min at 4 °C, and the pellet was resuspended in 50 ml of buffer A,
pH 8.0 (100 mM Na2HPO4, 10 mM Tris-HCl, pH 8.0, 1% Triton X-100, 1
mM -mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, and pro-
tease inhibitors). The resuspension was agitated gently overnight at
4 °C. After another sonication, the extract was centrifuged at 19,000 
g for 10 min at 4 °C. The pellet was resuspended in 10 ml of buffer B
(100 mM Na2HPO4, 10 mM Tris-HCl, pH 8.0, 6 M guanidine HCl, 1 mM
-mercaptoethanol, and protease inhibitors), and the suspension was
shaken at 4 °C for at least 6 h. After centrifugation at 19,000  g for 10
min at 4 °C, the supernatant containing p66 was collected. Renatura-
tion of p66 was achieved by diluting the p66 suspension dropwise into
a 100-fold excess of renaturation buffer with continual stirring (20 mM
Tris-HCl, pH 7.5, 200 mM ammonium sulfate, 10 mM magnesium ace-
tate, 1 mM DTT, and 10% glycerol). The protein was further purified by
Ni-NTA column chromatography. The column (500 l) was equilibrated
with 5 ml of renaturation buffer and charged three times with 500 g of
renaturated p66 protein. After washing the column with 5 ml of column
buffer (20 mM Tris-HCl, pH 7.5, 200 mM ammonium sulfate, 10 mM
magnesium acetate, 1 mM DTT, 10% glycerol, and 50 mM imidazole, pH
7.5), six fractions of 250 l were collected from the column with column
buffer containing 450 mM imidazole, pH 7.5, and protease inhibitors.
Preparation of the C-terminal Deleted p66 Protein Derivative—pBlue-
script SK containing the full-length KIAA0039 cDNA was digested
with NcoI and ApaI, which liberated a fragment of 1324 base pairs
whose sequence started just upstream of the first ATG codon of the p66
gene and stopped 80 base pairs before the stop codon. The truncation
resulted in the loss of the last 22 amino acids from the C terminus of
p66, which comprises the putative PCNA-binding domain. The frag-
ment was subjected to the 3-5 exonuclease and DNA polymerase
activities of T4 DNA polymerase, resulting in a blunt-ended fragment.
The fragment was then inserted by blunt end ligation into the blunt-
ended XhoI site of pET19b, which placed it downstream of the T7 lac
promoter and in frame with the His tag coding region. The synthesis of
products longer than that encoded by the inserted fragment is pre-
vented in this construct by the presence of a stop codon in each open
reading frame on the 3 side of the insertion. E. coli BLR DE3 was
transformed with the recombinant plasmid by electroporation, and the
truncated protein was expressed and purified as described for full-
length p66 protein.
Construction of Recombinant Baculoviruses Vectors Expressing p125,
p66, and p50—The open reading frames of the three subunits of human
DNA polymerase  (GenBankTM) were amplified by polymerase chain
reaction from 50 ng of HeLa cDNA using the Klenow polymerase mix
(CLONTECH, Palo Alto, CA) and the following primer sets designed
from sequences deposited in GenBankTM: p125, 5-GGGATGGATGGC-
AAGCGGCGGCCAGG-3 and 5-CCATGGGATGCTTGCAAGGTCAC-
CAGG-3; p66, 5-ACCATGGCGGACCAGCTTTATCTGG-3 and 5-CC-
AAGTCTCTGATCTACCAGAGATGG-3; and p50, 5-GCCATGTTTTC-
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TGAGCAGGCTGCCC-3 and 5-CAGCCTCCATCTGGGCCTCTC-
TGGTC-3.
The cycling parameters were: 94 °C for 60 s; 36 cycles at 94 °C for
30 s, and 67 °C for 3–5 min; and finally 10 min at 67 °C. The polymerase
chain reaction products were cloned into pCR2.1 topo (Invitrogen), the
sequences were verified by dideoxy sequencing, excised by EcoRI diges-
tion, and subcloned into EcoRI sites of the baculovirus transfer vectors
pVL1393 or pAcHLT-A (Pharmingen) for production of untagged or
histidine-tagged recombinant products, respectively. Recombinant
baculoviruses were generated by co-transfecting the appropriate bacu-
lovirus transfer vector containing the desired gene and Bsu36I linear-
ized Bakpak6 baculovirus DNA into insect Sf9 cells.
Insect Cell Culture and Purification of Recombinant DNA Polymerase
—The Sf9 cell line was maintained as a monolayer culture at 28 °C in
TC-100 medium (Life Technologies, Inc.) supplemented with 0.37 g/liter
-ketoglutaric acid, 0.4 g/liter -D-fructose, 0.055 g/liter fumaric acid,
0.67 g/liter malic acid, 0.06 g/liter succinic acid, 2.7 g/liter sucrose, 0.2
g/liter choline chloride, 0.2 g/liter -alanine, 0.35 g/liter NaHCO3, 3.33
g/liter lactalbumin hydrolysate, 100,000 units/liter penicillin, 0.1 g/liter
streptomycin, 0.25 mg/liter amphotericin B, and 10% fetal calf serum
(Life Technologies, Inc.). The medium was buffered to pH 6.2 using
NaOH. The cells were split every 4 days to maintain a density of 105
cells/ml. Recombinant baculoviruses (RBVs) were amplified to 108
plaque-forming units/ml and used for protein expression. Sf9 cells in
exponential phase were layered at a density of 5  105 cells/ml and
infected simultaneously with different RBVs. For a 175-cm2 cell culture,
dish cells were infected using 3 ml of RBV-p125, 2 ml of RBV-p66,
and/or 1 ml of RBV-p50.
After 2 days of incubation at 28 °C, the cells were harvested and
centrifuged at 400  g for 10 min. The pellets were washed twice with
ice-cold PBS. The cells were centrifuged and resuspended in 10 volumes
of hypotonic buffer (25 mM HEPES-KOH, pH 7.7, 5 mM KCl, and 1.5 mM
MgCl2) and immediately centrifuged at 800  g for 3 min. The cells
were resuspended in 5 volumes of hypotonic buffer containing protease
inhibitors. The suspension was left on ice for 10 min and lysed with 16
strokes of a Dounce homogenizer. After incubating on ice again for 20
min, the ionic strength was adjusted to 0.4 M NaCl followed by constant
mixing for 30 min. The cell extracts were cleared by centrifugation
(20,000  g for 30 min). The supernatant was adjusted to 5 mM imid-
azole, pH 7.7, and applied to a Ni-NTA column (1 ml for 10 175-cm2 cell
culture dishes) equilibrated beforehand in buffer A (25 mM HEPES-
KOH, pH 7.7, 0.4 M NaCl, 1.5 mM MgCl2, 5 mM imidazole, pH 7.7, and
10% glycerol). After washing with 20 volumes of buffer A, the column
was equilibrated with 10 volumes of buffer A containing 75 mM NaCl.
The proteins were eluted using buffer A containing 100 mM imidazole,
pH 7.7.
ELISAs—Incubations were done at room temperature, and the wells
were washed three times between each incubation step with PBS-T
unless otherwise indicated. To measure p66 binding to PCNA, a 96-well
ELISA plate was coated with 1 g of streptavidin in 50 l of PBS/well
for 1 h. The wells were then saturated by incubating them with 1% BSA
in PBS for 1 h. Various concentrations of biotinated PCNA or bio-
tinated, recombinant human RP-A were added to 50 ng of p66 in 50 l
of PBS containing 1% BSA, 0.1% Triton X-100, and 150 mM NaCl, and
the mixtures were incubated in the streptavidin-coated wells for 1 h.
After washing, mouse monoclonal antibody against p66 diluted 100-fold
in PBS-TM was then added to the wells and incubated for 1 h followed
by goat anti-mouse IgG peroxidase-conjugated secondary antibody, di-
luted 2000-fold in PBS-TM for 1 h. After three final washes in PBS-T,
the interactions were revealed by adding to each well 100 l of 0.4
mg/ml of o-phenylenediamine in a buffer containing 0.012% hydrogen
peroxide, 0.1 M citric acid, and 0.1 M Na2HPO4, pH 5.0. The reaction was
stopped with 0.1 M H2SO4, and the intensity of the yellow color was
measured at A450. The values were used as a measure of the interaction
between both proteins after correcting for the background values of
PCNA- or RP-A-uncoated wells. To demonstrate p21Cip1 inhibition of
the binding of the C-terminal domain of p66 to PCNA, the wells were
coated with a streptavidin-biotinated p66 peptide complex by adding 50
l of 20 g/ml streptavidin plus 100 ng of biotinated p66 peptide in PBS
to each well for 1 h. After rinsing the wells once with PBS, the remain-
ing binding capacity of the wells was saturated by filling them with 1%
BSA in PBS for 1 h. PCNA (30 ng in 50 l of PBS, 150 mM NaCl, 1%
BSA, and 0.1% Triton X-100) along with various concentrations of p21
peptide or mutated p21 peptide, were then added to the wells and
incubated for another hour. Anti-PCNA monoclonal antibody diluted
1000-fold in PBS-TM was then added to the wells and incubated for 2 h
followed by secondary antibody (goat peroxidase-conjugated anti-mouse
IgG) diluted 1000-fold in 50 l of PBS-TM for 1 h. The wells were rinsed
and processed as described above.
Pull-down Assays—The reaction mixtures contained 200 ng of wild-
type p66 along with the indicated amounts of biotinated PCNA or
biotinated human RP-A in reaction buffer (PBS, 350 mM NaCl, 1%
Triton X-100, and protease inhibitors). The reactions were incubated for
2 h at 30 °C. Then 20 l of a 50% suspension of streptavidin-agarose
beads was added to each tube followed by incubation on a shaker for
another 2 h at 30 °C. The tubes were centrifuged at 3,000  g for 2 min,
and the pellets were washed three times for 15 min at 37 °C by resus-
pending and centrifuging them in reaction buffer. After a fourth wash,
the beads were resuspended in 20 l of loading buffer. The samples
were processed for Western blotting with 100-fold diluted anti-p66
monoclonal antibody as described below. For the pull-down assays with
the PCNA mutant derivatives, the same amount of each derivative (0.5
g) was added to reactions containing 10 g of biotinated p66 peptide in
reaction buffer (PBS, 0.1% Triton X-100 and 1 mg/ml BSA). The reac-
tions were processed as described above except that 1000-fold diluted
monoclonal anti-PCNA antibody was employed for Western blotting
(see below). For pull-down assays of recombinant three- and two-sub-
unit DNA polymerase  complexes, 20 l of a 50% suspension of strepta-
vidin-agarose beads in PBS was added to purified two- and three-
subunit preparations of DNA polymerase  in PBS-T (500 l) containing
200 ng of biotinated PCNA. After 1 h of incubation at room temperature
with agitation, the beads were recuperated by centrifugation and
washed five times with PBS-T as described above, and the samples were
processed for Western blot analysis with anti-p125 antibody as de-
scribed below.
Kinase Assays—The reactions were performed in 10 l of reaction
mixture containing kinase buffer (25 mM Tris-HCl, pH 7.5, and 6 mM
MgCl2), 10 Ci of [-
32P]ATP (3000 Ci/mmol; PerkinElmer Life
Sciences), 1 M ATP, the indicated amounts of histone H1 or p66
protein, and 1 l of cyclin-Cdk complex. The reactions were incubated
for 20 min at 37 °C and stopped by adding 3 l of 200 mM Tris-HCl, pH
6.8, 8 mM EDTA, 4% (w/v) -mercaptoethanol, 32% (v/v) glycerol, and
0.1% (w/v) bromphenol blue. The samples were boiled and then sub-
jected to 12.5% SDS-PAGE. After drying, radioactive bands on the gel
were revealed by autoradiography of the gel with Fuji medical x-ray
film.
Immunofluorescence Microscopy—All operations were carried out at
room temperature unless indicated otherwise. HeLa cells were grown
on the surfaces of coverslips in 6-well culture plates containing Dulbec-
co’s modified Eagle’s medium (Life Technologies, Inc.) supplemented
with 10% fetal bovine serum, 2 mM glutamine, 100 g/ml penicillin, 100
units/ml streptomycin, and 1% nonessential amino acids (Life Technol-
ogies, Inc.) at 37 °C under a humidified atmosphere containing 5% CO2.
Exponentially growing cells were washed twice in PBS and fixed for 10
min in PBS containing 2% formaldehyde. The cells were then perme-
abilized in PBS containing 0.2% Triton X-100 for 5 min at 4 °C, washed
twice in PBS, and fixed for 20 min in methanol at 20 °C. After two
washes in PBS, the cells were incubated with 100 l of appropriate
dilutions of the one or both of the following antibodies diluted in PBS
containing 5% BSA for 1 h: PCNA-fluorescein isothiocyanate-conju-
gated monoclonal antibody (Ab-1, Oncogene) diluted 100-fold, p66
monoclonal antibody (2C11) diluted 100-fold, monoclonal PCNA anti-
body (PC10, Roche Molecular Biochemicals) diluted 600-fold, and goat
polyclonal antibody against the large subunit of DNA polymerase 
diluted 100-fold. The coverslips were washed three times in PBS-T.
Depending on the first antibody, the cells were then incubated as for the
first antibody with either one or both of the following secondary anti-
bodies; fluorescein isothiocyanate- or rhodamine-conjugated Affinipure
goat anti-mouse IgG diluted 100-fold (Jackson ImmunoReseach) or
rhodamine-conjugated donkey anti-goat IgG (Santa Cruz Biotechnolo-
gy). After three washes in PBS, the coverslips were incubated in 1 g/ml
of 4,6-diamidino-2-phenylindole in PBS for 5 min. Finally, after two
washes in PBS, coverslips were placed face down on a drop (2 l) of 100
mg/ml of DABCO in PBS and 50% glycerol and sealed with nail polish.
Fluorescent images were captured through a three-dimensional image
capture system on a DMRXA LEICA microscope using Metamorph
software (Universal Imaging). The images were deconvoluted using
software developed by Sibarita and DeMey.2
Co-immunoprecipitation Assays—200 l (700 g of protein) of par-
tially purified mouse FM3A cell extract (phosphocellulose 0.4 M frac-
tion) (30) was added to 160 l of PBS containing 40 l of the superna-
tant of the hybridoma clone 2C11 expressing p66 monoclonal
2 J. B. Sibarita and J. R. DeMey, manuscript in preparation.
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antibodies. The reactions were incubated on ice for 30 min, and immu-
nocomplexes were precipitated by adding 20 l of a 50% suspension of
protein G-Sepharose beads (Amersham Pharmacia Biotech) and centri-
fuging at 12,000 g for 2 min. After four washes with PBS, the samples
were processed for Western blotting with monoclonal anti-p66 and
anti-p125 antibodies as described below.
Western Blot Analysis—Samples along with prestained protein
standards (Bio-Rad) were boiled in loading buffer (50 mM Tris-HCl, pH
6.8, 2% SDS, 0.1% bromphenol blue, 10% glycerol, 100 mM DTT) and
subjected to 12.5% SDS-PAGE. After transfer to 0.45-m nitrocellulose
membranes, the membranes were blocked with PBS-TM for 30 min.
The blots were then incubated with the appropriate antibody diluted in
PBS-TM at 4 °C overnight. The blots were washed four times with
PBS-T for 5 min each, followed by incubation for 1 h with secondary
antibody, which was either horseradish peroxidase-conjugated goat an-
ti-mouse IgG or goat anti-rabbit IgG (Jackson Immunoresearch Labo-
ratories) or donkey anti-goat IgG (Santa Cruz) diluted 1:2000 in PBS-
TM. For anti-phosphoserine, anti-phosphothreonine, and anti-
phosphotyrosine antibodies, PBS-T containing 3% BSA was employed
for blocking and antibody dilution. The blots were washed four times in
PBS-T for 5 min each, and the membranes were incubated with the
chemiluminescence reagent of PerkinElmer Life Sciences and exposed
to Fuji medical x-ray film.
Far Western Blot Analysis—Proteins were transferred to 0.45-m
nitrocellulose membranes from a SDS-12.5% polyacrylamide gel. The
membrane was incubated in BLOTTO (25 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 5 mM KCl, 5% fat-free milk, 1% BSA, 0.05% Tween 20) for 1 h at
room temperature. The membrane was then incubated overnight at
4 °C in BLOTTO containing 1 g/ml of PCNA with constant agitation.
After three rinses with BLOTTO, the membrane was incubated with
monoclonal PCNA antibody (diluted 1:600) with or without the p21 or
mutated p21 peptides in BLOTTO for 3 h at room temperature. The
membrane was washed three times with BLOTTO and incubated for 1 h
with horseradish peroxidase-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch, diluted 1:2000) and further processed as described
above under Western blotting.
In Vitro DNA Synthesis—DNA replication assays were performed as
described previously (35). The template (0.25 g of DNA or 0.83 nmol of
nucleotide/reaction) was poly(dA)300 annealed to oligo(dT)12–18 (Amer-
sham Pharmacia Biotech) at a template-primer base ratio of 10:1.
Nucleotide was [methyl-3H]thymidine 5 triphosphate (Amersham
Pharmacia Biotech) at 0.5 Ci/reaction (0.38 mmol/Ci, 200 cpm/pmol
thymidine 5 triphosphate), corresponding to a final concentration of 10
M. The reactions were incubated at 37 °C for 60 min and processed for
counting as described previously (35).
RESULTS
Recombinant p66 Protein Binds to PCNA—Previously, we
showed that mammalian DNA polymerase  complexes con-
taining at least four subunits, a large catalytic subunit of 125
kDa, a small subunit of 48–50 kDa, and two novel components
of 66 and 38 kDa, can be isolated by PCNA affinity chromatog-
raphy (30). By immunoblot analyses, the 38-kDa component
was shown to be either the 38- or the 40-kDa subunit of repli-
cation factor C or both. The 66-kDa component was identified
as the product of the Kazusa cDNA clone KIAA0039. RNA
5-extension analysis showed that the cDNA was complete,
although potentially it would code for a protein of 51.5 kDa.
Retarded mobility on the SDS-polyacrylamide gel, caused by
the high charge/mass ratio of p66, was suggested to explain the
discrepancy between the observed and theoretical molecular
masses. The translated KIAA0039 cDNA sequence contains a
very good match to the extreme N-terminal and C-terminal
PCNA-binding sites found in a wide range of other PCNA-
binding proteins, including the third subunits of DNA polym-
erase  from yeast, Cdc27 and Pol32 (30) (Fig. 1A). This obser-
vation as well as the association of this protein with active
DNA polymerase  complexes from mouse (30), calf thymus
(31), and human (32) has led to the suggestion that p66 may be
the third subunit of DNA polymerase . To test this hypothesis,
we first of all purified recombinant human p66 protein from E.
coli (Fig. 1B) and tested its ability to bind to purified PCNA
(Fig. 1, C and D). His-tagged p66 protein was expressed as an
insoluble aggregate after 6 h of induction in E. coli. The insol-
uble pellet was resolubilized in 6 M guanidine HCl, rapidly
diluted into guanidine HCl free buffer to achieve renaturation,
and then further purified by Ni-NTA chromatography (see
“Materials and Methods”) (Fig. 1B). The binding between
PCNA and p66 was tested using modified ELISAs. Basically,
increasing amounts of biotinated human PCNA or biotinated
human RP-A as a control were bound to the bottom of a strepta-
vidin-coated 96-well ELISA plate, and constant amounts of
recombinant p66 protein were added to the wells. Fig. 1C
shows that p66 binding to the well was dependent on the
amount of prebound PCNA but not on the amount of prebound
RP-A. Likewise, in pull-down assays with streptavidin-coated
beads, the amount of p66 pulled down by the streptavidin-
coated beads depended on the amount of biotinated-PCNA pro-
tein added to the reactions. Only very little p66 was pulled
down in the absence of PCNA or in the presence of RP-A (Fig.
1D). These results indicate that p66 binds specifically to PCNA.
The Extreme C-terminal Region of p66 Mediates PCNA Bind-
ing—The extreme C-terminal region of p66 contains a consen-
sus PCNA-binding domain (Fig. 1A). To determine whether
this domain contributes to PCNA binding by p66, we deleted
the entire C-terminal region starting at amino acid 444, effec-
tively removing the 22-amino acid region containing the puta-
tive PCNA-binding domain. In Fig. 2A, increasing amounts of
p66 and the deleted p66 derivative were transferred to a nitro-
cellulose membrane for blotting with anti-p66 monoclonal an-
tibody (upper panel) or anti-PCNA monoclonal antibody (lower
panel) after incubation of the blot with PCNA (far Western
blotting). The results demonstrate that PCNA bound only very
weakly to the p66 deletion derivative lacking the PCNA-bind-
ing domain. Similarly, using the same ELISAs as described
above, the deleted p66 derivative showed markedly reduced
affinity for PCNA (Fig. 2B). These results indicate that the
C-terminal 22-amino acid region containing the PCNA-binding
FIG. 1. Recombinant p66 protein binds to PCNA. A, alignment of
canonical PCNA-binding domains of known PCNA-binding proteins,
including that of p66 (18). B, silver-stained SDS-polyacrylamide gel of
different purified fractions of p66 overexpressed in E. coli. Lanes 1 and
2, noninduced and induced E. coli extracts (3 g); lane 3, insoluble pellet
(0.5 g) resuspended in 6 M guanidine HCl; lane 4, eluted nickel column
fraction (0.5 g). C, ELISA of p66 binding to PCNA. A constant amount
of recombinant p66 protein (50 ng) was added to streptavidin-coated
wells containing increasing amounts (ng) of bound, biotinated PCNA
(closed circles) or biotinated human RP-A (open squares) (purified as
described in Ref. 36. The reactions were processed as described under
“Materials and Methods.” The absorbance at 450 nm indicates the level
of p66 binding to the wells. D, pull-down assays of p66 binding to
biotinated PCNA or biotinated human RP-A. The assays were per-
formed by incubating constant amounts of recombinant p66 (200 ng) to
reactions containing increasing amounts (in ng) of either biotinated
PCNA (upper panel) or biotinated human RP-A (lower panel) bound to
streptavidin beads. Immunoblots of the streptavidin-bound fractions
were probed with anti-p66 monoclonal antibodies.
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domain is critical for p66 binding to PCNA.
Affinity of the C-terminal Region of p66 for PCNA Derivatives
with Mutations in Exposed Loop Regions—Having established
that binding to PCNA requires the C-terminal region of p66, we
analyzed the regions on PCNA that are important for p66
binding. Pull-down assays were used to measure the affinity of
a biotinated peptide, containing the extreme C-terminal 22-
amino acid region of p66, for purified PCNA derivatives con-
taining alanine substitutions within the loop regions on the
surface of the PCNA trimer (for a detailed description of these
mutants see Ref. 18). The QLGI125 mutant showed severely
reduced binding affinity for the p66 peptide in the pull-down
assays (Fig. 3A). The mutant contains alanine substitutions in
residues Gln125, Leu126, Gly127, and Ile128 located within the
middle of the domain-interconnecting loop. The region has pre-
viously been suggested to form part of the binding site for DNA
polymerase  on the basis of experiments showing that PCNA
stimulation of DNA polymerase  is inhibited by monoclonal
antibodies that recognize residues 121–135 (37). This region is
also the site of the pol30–79 mutation (I126A,I128A) in S.
cerevisiae and that of other mutations (Val123, Leu126, Gly127,
and Ile128) affecting DNA polymerase  stimulation by PCNA
(38, 39). The remaining three mutants showed nearly normal
affinity for the p66 peptide, with the exception of LAPK251,
which contains a triple mutation in the C-terminal region.
However, this mutant has been suggested to aggregate (18),
indicating that the weak interaction with the p66 peptide may
reflect the inaccessibility of PCNA within the aggregate rather
than any direct block to p66 binding. The results of the binding
assays agree with the relative activities of the three PCNA
mutants in the DNA replication assay shown in Fig. 3B and
with the results of previous replication assays using the same
mutants (18). Nearly normal binding of the p66 peptide to
SHV43 and VDK188, which contain mutations within the hy-
drophobic pocket located on the C-side of the trimer and on the
prominent loop located on the rear side of the trimer, respec-
tively, suggests that these regions are not critical for p66 bind-
ing to PCNA.
The amino acids Gln125 and Gly127 that were targeted in the
QLG125 mutant are also involved in p21Cip1 binding to PCNA
(20). Moreover, only the QLG125 mutant showed a marked loss
of binding for p21Cip1 in band shift assays on native polyacryl-
amide gels (18). Thus, p66 binding to PCNA mimics that of
native DNA polymerase  and the region involved is also im-
portant for p21Cip1 binding. This suggests that the PCNA-
binding domain of p66 must be important for PCNA-dependent
DNA synthesis by DNA polymerase  and that competition
between p21Cip1 and p66 for the same binding site on PCNA
underlies p21Cip1 inhibition of DNA polymerase .
p21Cip1 Inhibits p66 Binding to PCNA and DNA Synthesis by
Native DNA Polymerase —The extreme C terminus of p21Cip1
contains the PCNA-binding domain that has been shown to
compete for DNA polymerase  binding to PCNA and inhibit
DNA synthesis by DNA polymerase  in vitro (18). In Fig. 4, we
show that a peptide of 22 amino acids containing the PCNA-
binding domain of p21Cip1 inhibits both p66 peptide binding to
PCNA and DNA synthesis by a mouse DNA polymerase 
fraction containing p66 (30) (Fig. 4B, inset). A similar peptide
(mutant p21 peptide) containing the entire C-terminal region of
p21Cip1 but with a substitution of isoleucine for alanine within
the consensus PCNA-binding domain was ineffective, confirm-
ing previous results that this amino acid is critical for p21Cip1
function (40). Competition between the PCNA-binding sites of
p21Cip1and p66 for binding to PCNA comforts the conjecture
that p21Cip1 and p66 recognize the same binding site on PCNA,
the middle of the domain interconnecting loop, and that this
competition causes inhibition of PCNA-dependent DNA polym-
erase  activity.
PCNA-dependent DNA Synthesis by Reconstituted Human
DNA Polymerase  Requires p66—Human DNA polymerase 
was reconstituted by co-expressing recombinant p125, p66, and
p48–50 subunits in the baculovirus system (see “Materials and
Methods”). The p48–50 subunit was tagged with six histidine
residues on its N-terminal side to facilitate purification of the
reconstituted DNA polymerase  complex by nickel-agarose
chromatography. Immunoblot analysis of the eluted fractions
from the Ni-NTA column showed that all three subunits were
eluted together, suggesting that the three subunits formed a
complex when co-expressed in Sf9 insect cells (Fig. 5A, inset).
Far Western analysis of the reconstituted complexes (Fig. 5A)
showed that only p66 interacted with PCNA. As with the C-
terminal p66 peptide described above, the interaction between
recombinant p66 and PCNA was inhibited by the wild-type
p21Cip1 peptide but not by the p21Cip1 peptide containing a
mutation within the PCNA-binding domain. The failure to
observe an interaction between PCNA and p125 subunit could
be attributed to either the disproportional low amount of p125
in the complex (data not shown) or to poor renaturation of p125
FIG. 2. p66 binding to PCNA depends on its C-terminal region.
A, Western blots. Increasing amounts (in ng) of recombinant wild-type
or C-terminal deleted p66 protein (p66 ) were transferred to nitrocel-
lulose membranes and probed either with anti-p66 monoclonal antibody
(upper panel) or anti-PCNA monoclonal antibody after incubation of the
membrane with PCNA (1 g/ml). B, ELISAs of the binding of wild-type
(closed triangles) and C-terminal deleted p66 (open triangles) (50 ng) to
increasing amounts of biotinated PCNA immobilized on the bottoms of
96-well ELISA plates. The absorbance at 450 nm indicates the level of
p66 binding to the wells.
FIG. 3. Replication and binding activities of wild-type and mu-
tant PCNA for the PCNA-binding domain of p66. A, pull-down
assays of the binding of wild-type and mutant PCNA to the 22-amino
acid C-terminal region of p66. A PCNA immunoblot of the streptavidin-
bound fractions from pull-down assays of biotinated p66 peptide (10 g)
binding to wild-type and mutant PCNA (0.5 g each) (see text for
details). The numbers below the lanes indicate the percentages of bound
PCNA to total input PCNA (P). LaneP, one fifth (100 ng) of the input
amount of PCNA; lane , without the p66 peptide; lane , with the p66
peptide. B, DNA replication activity of the PCNA mutants used in the
pull-down assays.
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on the membrane filter. To circumvent these problems, we did
pull-down assays by adding biotinated PCNA-coated streptavi-
din beads to fractions containing either the three subunit com-
plex or the two subunit complex lacking p66 (Fig. 5B). The p125
subunit was only pulled down when fractions containing the
three-subunit complex were employed. We failed to detect the
p125 band in pull-down assays with the two-subunit complex.
These results suggest that the p66 mainly mediates the inter-
action between p125 and PCNA.
In Fig. 5C we confirm these findings by showing that PCNA-
dependent DNA synthesis is only observed with the three-
subunit DNA polymerase  complex containing p66. The pres-
ence of p66 stimulated DNA synthesis by about 3–4-fold in the
presence but not in the absence of PCNA. This synthesis was
completely abolished by the p21Cip1 peptide but not by the
mutated p21Cip1 peptide. This indicates that PCNA-dependent
DNA synthesis by DNA polymerase  relies on the PCNA-
binding domain of p66. Also, these results further stress the
importance of p66 for observing the inhibitory action of p21Cip1.
On the other hand, basal DNA synthesis, which required the
two-subunit complex (data not shown), was neither stimulated
by PCNA nor inhibited by the p21Cip1 peptide, a result that
argues against the presence of a functional PCNA-binding do-
main in the large subunit. The result agrees with data showing
PCNA-independent DNA synthesis by the recombinant large
subunit alone (35, 41) but is at variance with results showing
that the recombinant two-subunit complex depends on PCNA
for activity (29).
Phosphorylation of p66—During the purification of DNA
polymerase  complexes from mouse cells we noticed that the
p66 band on Western blots interacted with antibodies directed
against phosphorylated threonine residues but not with anti-
bodies directed against phosphorylated serine (Fig. 6A, com-
pare lane 2 in middle and bottom panels). As expected the
recombinant p66 protein expressed in E. coli failed to interact
with either antibody (Fig. 6A, compare lane 1 in middle and
bottom panels). To test whether p66 is a substrate for Cdk
phosphorylation, purified p66 expressed in E. coli or histone H1
was incubated with purified complexes of CycE-Cdk2, CycA-
Cdk1, or CycA-Cdk2 in the presence of [-32P]ATP, and the
reaction products were run on a 12% SDS-polyacrylamide gel.
Autoradiography of the dried gel showed that p66 protein was
phosphorylated under these conditions irrespective of the na-
ture of the Cdk-cyclin complex employed. These results indi-
cate that p66 is a substrate for Cdk phosphorylation, at least in
vitro. To determine whether PCNA binding had any effect on
p66 phosphorylation by CycE-Cdk2, increasing concentrations
of PCNA were added to the p66 or histone phosphorylation
reactions. Fig. 6C shows that PCNA inhibited the phosphoryl-
ation of p66 at lower concentrations than those that inhibited
histone H1 phosphorylation, demonstrating that PCNA inter-
feres with the CycE-Cdk2 phosphorylation of p66. Similar re-
sults were obtained with the other cyclin-dependent Cdk com-
plexes (data not shown). Conversely, however, phosphorylation
did not block p66 binding to PCNA (data not shown). In accord-
ance with previous results, PCNA was not phosphorylated un-
der these conditions (Fig. 6C) (42).
p66 Monoclonal Antibodies Co-immunoprecipitate p66 and
FIG. 4. The C-terminal region of p21Cip1 inhibits p66 peptide
binding to PCNA and PCNA-dependent DNA synthesis by DNA
polymerase  in vitro. A, ELISAs of the effect of p21 (closed squares)
and mutant p21 (open squares) (p21M) peptides on p66 peptide binding
to PCNA. Each assay contained 0.1 g of immobilized biotinated p66
peptide and 30 ng of PCNA. The absorbance at 450 nm indicates the
level of PCNA binding to the wells. B, in vitro replication assays of DNA
synthesis by native three-subunit DNA polymerase  in the presence of
the p21 (closed squares) or mutant p21 (open squares) peptide. Repli-
cation assays were done as described under “Materials and Methods.”
Inset, silver-stained lane of an SDS-polyacrylamide gel of the PCNA-
purified DNA polymerase  complex used in the replication assays.
FIG. 5. p66 protein is essential for the PCNA-binding and PCNA-
dependent DNA synthesis activities of human DNA polymerase
. Recombinant three-subunit DNA polymerase  was partially purified
as described under “Materials and Methods.” A, partially purified DNA
polymerase , obtained from four 175-cm2 flasks of insect cells infected
with baculoviruses expressing the three subunits of DNA polymerase ,
was loaded across the entire width of a 12.5% SDS-PAGE and trans-
ferred to a nitrocellulose membrane. The membrane was cut into 13
equals strips. Each strip was incubated with 1 g/ml of PCNA and
different amounts of p21 (p21-pep.) or mutant p21 (p21M-pep.) peptides.
PCNA binding to the blot was revealed using PCNA monoclonal anti-
body PC10 antibody. Inset, Western blotting analysis of the Ni-NTA
column fraction used in the far Western blots. The presence of the three
subunits of DNA polymerase  was revealed by incubating the blot
successively with monoclonal antibody against p66 and polyclonal an-
tibodies against p50 and p125 as indicated. B, pull-down assays of the
binding of the large subunit of DNA polymerase  to PCNA in the
presence and absence of p66. Partially purified two-subunit or three-
subunit DNA polymerase  was incubated with biotinated PCNA (200
ng), and bound materials were pulled down with streptavidin-coated
beads as described under “Materials and Methods.” Lanes T, one-tenth
of the total amount of purified fraction added to the assays; lanes B, all
of the eluted material from the streptavidin beads. The immunoblot was
probed with polyclonal p125 antibody (see “Materials and Methods”). C,
in vitro DNA replication assays of partially purified two-subunit and
three-subunit DNA polymerase . Ni-NTA column fractions were dia-
lyzed against DNA polymerase assay buffer, and 2 l of either the
two-subunit or three-subunit DNA polymerase  fraction was added to
each assay along with 0.1 g of PCNA where indicated (see “Materials
and Methods”). When present, p21 or mutant p21 (p21M) peptide was
added at 3.5 ng/assay.
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the p125 Subunit of DNA Polymerase —To demonstrate un-
equivocally that p66 is part of native DNA polymerase , we
attempted to co-immunoprecipitate the p125 subunit of DNA
polymerase  by incubating a 0.4 M phosphocellulose fraction
from mouse cells, which was shown previously to be enriched in
DNA polymerase  (30), with monoclonal antibodies against
p66. Fig. 7 shows that the p125 was effectively co-immunopre-
cipitated with p66 under these conditions, demonstrating that
both proteins form a complex in vivo. However, it should be
noted that only about 10% of the amount of p125 in the extract
was immunoprecipitated, whereas over 50% of p66 was precip-
itated under the same conditions (data not shown; compare the
intensity of the p125 band in the supernatant (one-tenth of
input) and precipitated fractions in Fig. 7), perhaps indicating
that p125 and p66 exist as free entities or form complexes with
other proteins in vivo.
Co-localization of p66 with PCNA and p125 within Nuclear
Structures Resembling S Phase DNA Replication Foci—PCNA
has been shown to form discrete foci within the nucleus during
the S phase of the cell cycle. These foci have been shown to
correspond to active centers of DNA replication (43, 44). Other
proteins directly involved in DNA replication or post-replica-
tive events, including the single-stranded DNA-binding protein
RP-A, DNA ligase 1, deoxycytosine methyltransferase, and
chromatin assembly factor 1 also co-localize with PCNA to
these replication foci, also referred to as “replication factories”
(44). In a growing number of instances, co-localization of cer-
tain of these proteins has been shown to depend on the pres-
ence of a consensus PCNA-binding motif in their extreme C-
terminal or N-terminal regions, leading to the interpretation
that PCNA, besides its direct role in DNA synthesis, also func-
tions to localize proteins to the replication factories where they
are required either during or after the replication process (45).
We were thus interested in seeing whether p66 would also be
co-localized to these replication factories. The histochemical
immunolocalization studies shown in Fig. 8 show this to be
effectively the case. In the two upper rows of panels, fluorescein
isothiocyanate-conjugated monoclonal antibodies against
PCNA reveal the typical pattern of PCNA localization within
nuclei of HeLa cells. As expected, most, but not all, of these foci
co-localized with the large subunit of DNA polymerase  (Fig. 8,
top panels), confirming that PCNA and polymerase  act to-
gether to accomplish DNA replication in these cells. Mono-
clonal antibodies against p66 monoclonal also gave a punctuate
pattern within nuclei (Fig. 8, middle and bottom panels); how-
ever, only a limited number of these foci co-localized with
PCNA and p125 foci (Fig. 8, middle and bottom panels). Al-
though these results demonstrate that p66 is part of a limited
number of replication foci, the results also suggest that p66
may be engaged in other activities occurring in the absence of
PCNA or p125. This will be discussed in more detail below.
DISCUSSION
Taken together, the findings presented here strongly suggest
that p66 is the subunit that bridges the catalytic activity of
DNA polymerase  to PCNA for processive DNA synthesis at
the replication fork in human cells. As expected from the pres-
ence of a canonical PCNA-binding domain present in the C
terminus of p66, the subunit interacted with PCNA, and the
interaction was almost entirely dependent on the PCNA-bind-
ing domain (Figs. 1 and 2). From this point of view, p66
strongly resembles the third subunit of S. pombe DNA polym-
erase , Cdc27, whose binding to PCNA relies on a PCNA-
binding domain located in its C terminus, a region that shows
significant homology to the PCNA-binding region of p66 (23).
The interaction between the C-terminal region of p66 and
PCNA was compromised by the same mutations within the
domain-interconnecting loop region that compromised DNA
synthesis by three-subunit DNA polymerase  in vitro (Fig. 3)
(18). So far, only proteins containing the canonical PCNA-
binding domain, such as Fen1 and p21Cip1, have been shown to
depend on this region for their interaction with PCNA (46). In
vitro results obtained with two S. pombe thermosensitive p125
mutants showed that only a limited decrease in PCNA stimu-
lation at the restrictive temperature, probably because of over-
all modification of the DNA polymerase  complex (47). Because
neither p125 nor p50 contain a canonical PCNA-binding do-
main, these results suggest that p66 is the main mediator of
PCNA-dependent synthesis by DNA polymerase . These con-
clusions were further substantiated and confirmed by experi-
ments employing the C-terminal domain of p21Cip1 and recon-
stituted DNA polymerase . As expected the PCNA-binding
domain of p21Cip1 competed with p66 binding to PCNA and
inhibited DNA replication by the native three-subunit DNA
polymerase  in vitro (Fig. 4). Thus, a major target for the
inhibitory action of p21Cip1 on DNA synthesis would be the
FIG. 6. Phosphorylation of p66. A, immunoblots of recombinant
and native p66 protein probed with monoclonal p66 antibody and anti-
bodies against various phosphorylated amino acids. Top panel, recom-
binant p66 (75 ng) from E. coli (lane 1) and native p66 (lane 2) purified
as part of the mouse DNA polymerase  complex (see inset in Fig. 4B)
were probed with p66 monoclonal antibody. Middle panel, the same blot
probed with anti-phosphothreonine antibody. Bottom panel, the same
blot probed with anti-phosphoserine antibody. B, phosphorylation of
recombinant p66 protein (E. coli) and histone H1 by cyclin-Cdk com-
plexes (CycA-Cdk1, CycA-Cdk2, and CycE-Cdk2). The numbers above
the lanes indicate the amount of p66 protein (in ng) or histone H1 added
to the assays. See “Materials and Methods” for details. C, PCNA inhib-
its p66 phosphorylation by CycE-Cdk2. The indicated amounts (in ng) of
PCNA were added to the standard phosphorylation assay.
FIG. 7. The large subunit of native three-subunit DNA polym-
erase  co-immunoprecipitates with p66. Co-immunoprecipitation
assays were performed as described under “Materials and Methods.” IP,
extracts were incubated with protein G-Sepharose beads and anti-p66
monoclonal antibody. NIP, extracts were incubated with protein G-
Sepharose beads alone. Lanes S, one-tenth of the extract added to the
assays; lanes P, all of the protein G-Sepharose-bound material. Failure
to observe p66 in the NIP supernatant(s) was due to occlusion of the p66
band by the large amount of bovine serum albumin in the p66 hybri-
doma supernatants, which migrates to nearly the same position as p66
during SDS-PAGE electrophoresis.
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interaction between p66 and PCNA. The reconstitution exper-
iments confirm this conjecture. PCNA-dependent synthesis
was only observed with the three-subunit complex, and only
the PCNA-dependent replication of the three-subunit complex
could be inhibited by the p21Cip1 peptide. We could neither
stimulate the two-subunit complex with PCNA nor inhibit its
activity with the p21Cip1 peptide (Fig. 5C). Furthermore, only
recombinant p66 on far Western blots interacted with PCNA
(Fig. 5A) and p66 was absolutely required to obtain pull-down
of the catalytic subunit (p125) using biotinated PCNA-coated
streptavidin-agarose beads (Fig. 5B). Although these results
further stress the fundamental importance of p66 for observing
PCNA-dependent DNA synthesis by DNA polymerase , they
contradict previous results obtained by other investigators us-
ing native and reconstituted DNA polymerase . Prominent
among these is the observation that native DNA polymerase 
has been consistently published as a two-subunit complex
whose activity depends on PCNA. However, as recently shown
for purified calf thymus DNA polymerase  (31), these com-
plexes may have contained p66 or small proteolytic fragments
of p66 that may not necessarily have been visible or recogniz-
able even on silver-stained SDS-polyacrylamide gels. Our fail-
ure to observe PCNA stimulation of the two subunit complex
also seems to be in conflict with previous results showing that
PCNA stimulates the activity of a two-subunit complex recon-
stituted from recombinant baculovirus infected insect cells but
agrees with data showing that PCNA is not required to activate
the large subunit alone (35, 41). Our results are also in accord
with those of Shikata et al. (32), who recently reported the
successful reconstitution and purification of an active three-
subunit but not an active two-subunit DNA polymerase .
These discrepancies may reflect differences under “Experimen-
tal Procedures” or contamination of recombinant enzymes with
insect proteins that functionally complement one or more of the
subunits of human DNA polymerase .
Arguing for the existence of at least one more PCNA-binding
site in human DNA polymerase , DNA polymerase  from S.
cerevisiae and S. pombe can be reconstituted as active two- or
three-subunit complexes (21, 24). The two-subunit complexes
lacking Pol32 or Cdc27 depend on PCNA for their activity,
although much higher amounts of PCNA are required com-
pared with three-subunit complexes (21, 24). Thus, yeast DNA
polymerases must possess alternative PCNA-binding do-
main(s) distinct from those found in the extreme C termini of
Pol32 and Cdc27. Indeed, the pol32 gene of S. cerevisiae is not
essential (25). An answer as to whether human DNA polymer-
ase  relies solely on p66 for interaction with PCNA might be
obtained by studying the activity of reconstituted DNA polym-
erase  complexes containing p66 derivatives mutated for the
PCNA-binding domain.
These considerations have important implications for nucle-
otide excision repair carried out by DNA polymerase . Al-
though this DNA repair is widely accepted to be dependent on
PCNA, the effect of p21Cip1 on the resynthesis step has been
controversial. Some laboratories have reported almost no effect
(15), whereas others have equal or nearly equal (48, 49) inhi-
bition of replicative DNA synthesis and repair synthesis by
p21Cip1. Our results showing p21Cip1 inhibition of p66 binding
to PCNA and specific inhibition of PCNA-dependent DNA syn-
thesis dependent on p66 (Fig. 5C) would seem to argue that
p21Cip1 inhibits both repair and replicative DNA synthesis
equally well by abrogating p66 binding to PCNA. However, the
situation may be more complicated. Only very few assays of
p21Cip1 inhibitory activity have employed purified DNA polym-
erase  and PCNA preparations. Most assays have been done in
crude cell extracts, in vivo, or in reconstituted systems contain-
ing many other factors that have been shown to interact with
PCNA and whose activities could be potentially inhibited by
p21Cip1. Thus, the differential effects of p21Cip1 on excision
repair synthesis may reflect the varying amounts of these
factors in the assays and not the presence of multiple sites with
different affinities for PCNA on DNA polymerase .
Figs. 7 and 8 show that p66 is an integral part of DNA
polymerase  and co-localizes with PCNA and the catalytic
subunit of DNA polymerase  within replication foci. Surpris-
ingly, however, most p66 foci did not co-localize with PCNA or
DNA polymerase . Also, not all PCNA or p125 foci co-localized
with p66. Although the latter may have been due to the strin-
gent conditions used to fix the cells, which might have resulted
in the loss of loosely associated p66 from the replication foci,
FIG. 8. Immunolocalization of p66
with PCNA and p125 within the rep-
lication foci of HeLa cells. Top row,
nuclear immunolocalization of PCNA and
p125. Middle row, nuclear immunolocal-
ization of PCNA and p66. Bottom row,
nuclear immunolocalization of p66 and
p125. Left-hand side frames, 4,6-dia-
midino-2-phenylindole staining. For de-
tails about the experimental procedures
and the identity of the various antibodies
employed, see “Materials and Methods.”
p66 Mediates PCNA-dependent Replication by DNA Polymerase  49265
the former might suggest that p66 plays other roles in S phase
nuclei. In agreement with this interpretation, there exists
mounting evidence to suggest that the functional homologue of
p66, Pol32, plays other important roles in DNA repair and
perhaps in other events during S phase. In S. cerevisiae, Pol32
has been shown to be involved in the RAD6/REV3 pathway for
UV radiation-induced mutagenesis where it may facilitate cou-
pling of SRS2 helicase activity to DNA synthesis by DNA
polymerase  (50). Also, Pol32 is required for coupling DNA
synthesis by DNA polymerase  to WRN helicase unwinding of
tetraduplex and hairpin structures (51). Indeed, WRN has been
shown to interact directly with DNA polymerase  (52). Impli-
cation of pol32 in DNA helicase activity is reminiscent of the 
subunit of DNA polymerase III of E. coli, which plays the dual
role of bridging the catalytic core of the functional equivalent of
PCNA, subunit , to DnaB, the replicative DNA helicase (53).
The p66 protein may play a similar dual role in mammalian
cells.
p66 protein isolated from mouse cells interacted specifically
with anti-phosphothreonine antibodies, suggesting that it is
phosphorylated in vivo (Fig. 6A). In vitro phosphorylation as-
says also showed that it was a substrate for phosphorylation by
Cdk1 and Cdk2 kinases (Fig. 6B). However, there exists only
one possible Cdk phosphorylation site in p66 located within the
sequence 273KLATPAGLK281, although the sequence is not
conserved in other putative p66 homologues from other species
(data not shown). The in vitro phosphorylation of p66 was
inhibited by PCNA (Fig. 6C), suggesting that p66 may be
maintained in an unphosphorylated state when complexed to
PCNA. The unphosphorylated state of DNA ligase I was also
shown to depend on the PCNA-binding site located within the
sequence that targets DNA ligase I to replication foci during S
phase. Dephosphorylation was suggested to be due to PCNA
occlusion of the phosphorylated serine residue, which lies close
to the PCNA-binding domain, and to be important for the
establishment of the prereplicative form of DNA ligase I (54). A
similar mechanism might control p66 activity and/or modulate
p66 targeting to replication complexes. The nature of the even-
tual role of p66 phosphorylation might be forthcoming from
experiments designed to identify the residue(s) involved, the
phosphorylated state of p66 during the cell cycle, and the
relative activities of reconstituted DNA polymerase  com-
plexes containing phosphorylated or unphosphorylated p66.
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